Literature DB >> 28079487

Adopting universal testing for HIV in intensive care for patients admitted with severe pneumonia: results from our change in practice.

Rory Sharvill1, Arnold Fernandes1, Kate Allen1, Jeremy Astin1.   

Abstract

Early identification of HIV infection is of obvious benefit to patients' health, yet many remain unaware of their diagnosis, with detrimental consequences. Current guidelines suggest patients with pneumonia are offered an HIV test. Early diagnosis of HIV infection in critically ill patients within intensive care is vital in reducing mortality and morbidity. In 2015, we established automated HIV testing for patients with pneumonia admitted to our intensive care unit. Prior to our change in practice, our HIV testing rate in patients with pneumonia was 29% within two weeks of admission. After implementation, 80% of patients with pneumonia were tested for HIV within 48 h (73% with 24 h). This intervention also facilitated an early and unexpected HIV diagnosis in one patient, which then allowed prompt tailored therapy and was a significant factor in their survival. Based on our success, we suggest other centres may benefit from employing a similar automated HIV testing system, especially in targeted patient groups such as severe pneumonia.

Entities:  

Keywords:  AIDS; Europe; HIV; screening

Mesh:

Year:  2016        PMID: 28079487     DOI: 10.1177/0956462416675108

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  2 in total

Review 1.  Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART.

Authors:  Catia Cillóniz; Antonella Ielpo; Antoni Torres
Journal:  Curr Infect Dis Rep       Date:  2018-09-10       Impact factor: 3.725

2.  HIV testing strategies employed in health care settings in the European Union/European Economic Area (EU/EEA): evidence from a systematic review.

Authors:  S Desai; L Tavoschi; A K Sullivan; L Combs; D Raben; V Delpech; S F Jakobsen; A J Amato-Gauci; S Croxford
Journal:  HIV Med       Date:  2019-11-14       Impact factor: 3.180

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.